

Introducing




Engineered Cells

SYNTHEGO



**Full Stack
Genome
Engineering**



[Synthego.com/cshl](https://synthego.com/cshl)

Transforming Cutting-Edge Research into Industry-Leading Therapeutics

*The Industry's First Non-viral Solution That Can Help
Accelerate Your Cell Product to the Clinic*

Delivering the ideal combination of advanced technologies, scientific expertise, and technical support – MaxCyte offers a powerful platform to help accelerate your path to the clinic and obtain the therapeutic index you require.

- High efficiency and viability
- Reproducibility
- Seamless scalability
- Proven clinical success

www.MaxCyte.com

Any Cell. Any Molecule. Any Scale.®

 **MaxCyte**®





Life Science Alliance

New not-for-profit open-access journal now online!

EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press join forces to empower authors to publish new research more efficiently.

Life Science Alliance is a new global, open-access, editorially independent, peer-reviewed journal committed to rapid, fair, and transparent publication of valuable research from across all areas in the life sciences.

Papers published in *Life Science Alliance* meet high scientific and editorial standards established by the alliance partners. *Life Science Alliance* welcomes new results, important confirmatory, negative, and refuting data, as well as community resources such as datasets, screens, and new methods.

Manuscripts can be submitted to *Life Science Alliance* directly or by seamless transfer without reformatting from nine partner journals: *The EMBO Journal*, *EMBO reports*, *Molecular Systems Biology*, *EMBO Molecular Medicine*, *Journal of Cell Biology*, *Journal of Experimental Medicine*, *Journal of General Physiology*, *Genes & Development*, and *Genome Research*.

Authors of papers transferred to *Life Science Alliance* with or without referee reports are given a firm commitment prior to transfer. Timely editorial decisions are made through collaborative consultation between the editorial team and leading academic scientists. No more than one round of substantive revisions will be requested.

Life Science Alliance: an initiative of three distinguished publishing organizations that offers authors a new and attractive choice among not-for-profit, open-access journals.

Learn more, sign up for alerts, and submit your research at:

www.life-science-alliance.org

SAVE THE DATE!

JOIN US IN SAN DIEGO!

AACR ANNUAL MEETING 2020

THE SAN DIEGO CONVENTION CENTER APRIL 25-29



For more information
as it becomes available, visit

[AACR.org](https://www.aacr.org)

AACR

American Association
for Cancer Research®

FINDING CURES TOGETHER®

Superior mRNA Therapeutics Start **HERE**

TriLink® CleanCap™ technology sets a new standard for superior mRNA translation.




COST: Lowest cost per milligram of biologically active Cap 1 mRNA due to increased yield - **lower than ARCA!**

TIME: Simplified transcription process - "Single pot" reaction to produce a Cap 1 structure


EFFICIENCY: 90-99% capping efficiency. Reduced cellular innate immune response with natural Cap 1 mRNA




Successful development of mRNA therapeutics relies on reproducible, high-efficiency production of capped mRNA. CleanCap™ uses a new co-transcriptional chemical process for the highest level of mRNA capping:



LC-MS Capping Analysis



ARCA EGFP mRNA



CleanCap™ EGFP mRNA

Available as:

CleanCap™
mRNA -
catalog &
custom



CleanCap™
reagents



CleanCap™
synthesis
services



The comparison is clear.

Visit **CleanCapmRNA.com** to see even more proof.